Skip to main content
Canna~Fangled Abstracts

Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders

By December 17, 2020No Comments

. 2021;1264:93-110.

doi: 10.1007/978-3-030-57369-0_7.

Victoria Golub 1, D Samba Reddy 2
Affiliations 

Abstract

Cannabis-derived cannabinoids have neuroactive properties. Recently, there has been emerging interest in the use of cannabidiol (CBD)-enriched products for treatment of drug-resistant epilepsy. In 2018, the FDA approved the use of CBD-rich Epidiolex for two severe forms of epilepsy in children (Lennox-Gastaut and Dravet syndromes). Experimental research supports the use of CBD in many CNS disorders, though the mechanisms underlying its anticonvulsant and neuroprotective effects remain unclear. CBD has been shown to reduce inflammation, protect against neuronal loss, normalize neurogenesis, and act as an antioxidant. These actions appear to be due to the multimodal mechanism of action of CBD in the brain. This chapter briefly describes the current information on cannabis pharmacology with an emphasis on the clinical utility of CBD in the treatment of refractory epilepsies and other related seizure conditions. Clinical trials are ongoing for other forms of epilepsy and refractory seizures associated with infantile spasms, tuberous sclerosis, and Rett syndrome. Overall, adjunct CBD has been found to be generally safe and effective for treatment-resistant seizures in children with severe early-onset epilepsy. Whether an add-on CBD is efficacious for the long-term treatment of various epilepsy and seizure types in adults being tested in various clinical trials.

 

Keywords: CBD, THC, Cannabidiol, Cannabis, Epilepsy, Marijuana, Refractory seizure

References

    1. Ames FR, Cridland S (1986) Anticonvulsant effect of cannabidiol. S Afr Med J 69:14–18 – PubMed
    1. Autry AR, Trevathan E, Van Naarden Braun K, Yeargin-Allsopp M (2010) Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms. J Child Neurol 25(4):441–447 – PubMed – DOI
    1. Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA, Almeida OF, Sousa N (2009) The mood improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 14(8):764–773 – PubMed – DOI
    1. Billakota S, Devinsky O, Marsh E (2019) Cannabinoid therapy in epilepsy. Curr Opin Neurol 32(2):220–226 – PubMed – DOI
    1. Birnbaum AK, Karanam A, Marino SE, Barkley CM, Remmel RP, Roslawski M, Gramling-Aden M, Leppik IE (2019) Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia 60(8):1586–1592 – PubMed – DOI

Leave a Reply